摘要
经过60余年的发展,随着对梗阻性肥厚型心肌病的病理生理学理解的加深,室间隔心肌切除术的应用范围和切除厚度明显增加,术中同时处理异常的二尖瓣装置,成为新的标准治疗方案。由于该术式难度高,能够常规开展的中心不多,且新型药物陆续研发,介入治疗技术不断进步,梗阻性肥厚型心肌病外科治疗的发展面临诸多挑战。同时,一代代心血管外科医师为改进和推广室间隔心肌切除术而不断尝试与创新,一方面改进器械和改善术野,另一方面利用先进技术完善手术规划,成为外科治疗发展的重要方向。室间隔心肌切除术的远期疗效已获得广泛证实,外科医师唯有不畏挑战,共同推动梗阻性肥厚型心肌病外科治疗接续发展,以守卫人民生命健康。
After more than 60 years of development,with the deepening of the pathophysiological understanding of obstructive hypertrophic cardiomyopathy,the extent and resection thickness of myectomy have increased significantly.Myectomy combined with the correction of anomalies of the mitral valve apparatus has become the standard treatment of obstructive hypertrophic cardiomyopathy.Only a few centers worldwide can routinely perform it due to the difficulty.Because of the advances of new drugs and interventional therapy,the development of surgical treatment faces many challenges.At the same time,generations of cardiovascular surgeons are constantly trying to promote septal myectomy,including developing devices and the surgical field,as well as improving surgical planning by advanced technology.At present,the superior long-term efficacy of septal myectomy has been confirmed.It is necessary to work together to promote the treatment of hypertrophic obstructive cardiomyopathy,so as to guard people′s health.
作者
郭惠明
魏培坚
Guo Huiming;Wei Peijian(Department of Cardiovascular Surgery,Guangdong Provincial People′s Hospital,Guangdong Academy of Medical Sciences,Guangdong Cardiovascular Institute,Guangdong Provincial Key Laboratory of South China Structural Heart Disease,Guangzhou 510080,China)
出处
《中华外科杂志》
CAS
CSCD
北大核心
2023年第3期181-186,共6页
Chinese Journal of Surgery
基金
广东省科技计划(2020B1111170011)
广州市科技计划(202201010768)
广东省人民医院心血管专项(2020XXG010)。
关键词
心肌病
肥厚性
心脏外科手术
心肌切除术
Cardiomyopathy,hypertrophic
Cardiac surgical procedures
Myectomy
作者简介
通信作者:郭惠明,Email:guohuiming@gdph.org.cn。
